ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 773 • 2019 ACR/ARP Annual Meeting

    Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation

    Megan Simonds 1, Amanda Schlefman 1, Suzanne McCahan 1, Kathleen Sullivan 2, Carlos Rose 3 and AnneMarie Brescia3, 1Nemours Biomedical Research, Wilmington, DE, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Nemours/ Alfred I DuPont Hospital for Children, Wilmington, DE

    Background/Purpose: Progression of Juvenile Idiopathic Arthritis (JIA) can lead to growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a key role in the pathogenesis…
  • Abstract Number: 1883 • 2019 ACR/ARP Annual Meeting

    Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients

    Jaymin Upadhyay1, Diana Sibai 1, Robert Labadie 2, Jordan Lemme 3, Christine Sieberg 2, Kirsten Ecklund 4, David Borsook 4 and Robert Sundel 4, 1Boston Children's Hospital, Harvard Medical School, Boston, MA, 2Boston Children’s Hospital, Harvard Medical School, Boston, MA, 3Boston Children's Hospital, Harvard Medical School, Boston, 4Boston Children’s Hospital, Harvard Medical School, Boston

    Background/Purpose: Despite a broad range of available therapeutics, pain remains poorly treated in many juvenile idiopathic arthritis (JIA) patients1-2. For some patients, the level of pain…
  • Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting

    Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis

    Daniah Basodan1, Kathleen M Andersen 2, Xintong Li 3, Jeffrey Curtis 4 and G. Caleb Alexander 5, 1University of Alberta, Edmonton, AB, Canada, 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, 3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 4University of Alabama at Birmingham, Birmingham, AL, 5Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD

    Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…
  • Abstract Number: 779 • 2019 ACR/ARP Annual Meeting

    The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants

    Kaiyu Jiang 1, Yungki Park 1, Tarbell Evan 1, Tao Liu 2 and James N. Jarvis3, 1University at Buffalo Jacobs School of Medicine, Buffalo, NY, 2Roswell Park Cancer Instiyute, Buffalo, NY, 3University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY

    Background/Purpose: IL2RA has been identified as a JIA-associated risk locus using both candidate gene and genetic fine mapping approaches.  However, numerous gene expression studies comparing…
  • Abstract Number: 1920 • 2019 ACR/ARP Annual Meeting

    School Nurse Education for Juvenile Idiopathic Arthritis

    W. Blaine Lapin1, Carleigh Kutac 2, Danielle Guttman-Lapin 3, Amanda Brown 2, Eyal Muscal 2 and Filiz Seeborg 2, 1Baylor College of Medicine, Connecticut Children's Medical Center, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3Aldine Independent School District, Houston, TX

    Background/Purpose: There is a paucity of literature on the challenges children with JIA face at school. Despite treatment advances, children with JIA often rate their…
  • Abstract Number: 2712 • 2019 ACR/ARP Annual Meeting

    Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

    Natalie Shiff1, Aimee Lougee 2, Roland Matsouaka 2, David Collier 3, Yukiko Kimura 4, Dax Rumsey 5, Jennifer Schenfeld 6, Scott Stryker 3, Marinka Twilt 7 and Timothy Beukelman 8, 1University of Florida, Gainesville, FL, 2Duke University, Durham, NC, 3Amgen Inc., Thousand Oaks, CA, 4Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, 5University of Alberta, Edmonton, AB, Canada, 6Amgen, Inc, Thousand Oaks, CA, 7University of Calgary, Calgary, AB, Canada, 8University of Alabama Birmingham, Birmingham, AL

    Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
  • Abstract Number: 781 • 2019 ACR/ARP Annual Meeting

    Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?

    Charlene Foley1, Achilleas Floudas 2, Sharon Ansboro 2, Mary Canavan 2, Monika Biniecka 2, Emma Jane MacDermott 3, Ronan Mullan 4, Gerry Wilson 5, Ursula Fearon 6 and Orla Killeen 7, 1Great Ormond Street Hospital, London, Ireland, 2TBSI, Dublin, Ireland, 3OLCHC, Dublin, Ireland, 4Tallaght Hospital, Dublin, Ireland, 5UCD, Dublin, Ireland, 6TBSI, Dublin, 7National Centre for Paediatric Rheumatology (NCPR), Our Lady’s Children’s Hospital Crumlin (OLCHC), Dublin, Ireland

    Background/Purpose: Down syndrome associated Arthritis (DA) is 20 times more common than JIA. It is an erosive, polyarticular RF negative arthritis with predominance in the…
  • Abstract Number: 1921 • 2019 ACR/ARP Annual Meeting

    Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

    Gaëlle Chédeville1, Michelle Batthish 2, Roberta Berard 3, Roxana Bolaria 4, Alessandra Bruns 5, David Cabral 6, Ciaran Duffy 7, Kerstin Gerhold 8, Tommy Gerschman 6, Jean-Philippe Proulx-Gauthier 9, Alan Rosenberg 10, Dax Rumsey 11, Heinrike Schmeling 12, Natalie Shiff 13, Gordon Soon 14, Lori Tucker 15 and Jaime Guzman 6, 1The Montreal Children's Hospital, McGill University, Montreal, Canada, 2McMaster University, Hamilton, Canada, 3Children's Hospital, London Health Sciences Centre, London, Canada, 4University of British Columbia, Victoria, BC, Canada, 5Université de Sherbrooke, Sherbrooke, QC, Canada, 6University of British Columbia, Vancouver, BC, Canada, 7University of Ottawa, Ottawa, ON, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Université Laval, Québec, QC, Canada, 10University of Saskatchewan, Saskatoon, SK, Canada, 11University of Alberta, Edmonton, AB, Canada, 12Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 13University of Florida, Gainesville, FL, 14University of Toronto, Toronto, ON, Canada, 15British Columbia Children’s Hospital, Vancouver, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and many medications are available to control the disease. While physician-reported adverse…
  • Abstract Number: 2714 • 2019 ACR/ARP Annual Meeting

    Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry

    Melissa Mannion1, Fenglong Xie 2 and Timothy Beukelman 3, 1University of Alabama at Birmingham, Alabama, 2University of Alabama at Birmingham, Birmingham, 3University of Alabama Birmingham, Birmingham, AL

    Background/Purpose: Inactive disease is the stated goal of treatment in juvenile idiopathic arthritis (JIA) and is typically measured by a composite score that combines several…
  • Abstract Number: 782 • 2019 ACR/ARP Annual Meeting

    Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion

    Erdal Sag1, Selcan Demir 2, Morten A. Nielsen 3, Malene Hvid 4, Egemen Turhan 5, Yelda Bilginer 2, Seza Ozen 6 and Bent Deleuran 7, 1Hacettepe University, Ankara, Turkey, 2Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey, 3Department of Biomedicine, Aarhus University, Aarhus, Denmark, 4Department of Biomedicine; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 5Department of Orthopedics and Traumatology, Hacettepe University, Ankara, Turkey, 6Hacettepe University Hospital, Ankara, Turkey, 7Department of Biomedicine; Department of Rheumatology, Aarhus University, Aarhus, Denmark

    Background/Purpose: Activated T cells are involved in the pathogenesis of the synovitis in oligoarticular Juvenile Idiopathic Arthritis (o-JIA). T cell activation is counter-balanced via co-inhibitory…
  • Abstract Number: 1923 • 2019 ACR/ARP Annual Meeting

    Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials

    Hermine Brunner1, Chen Chen 1, Alberto Martini 2, Graciela Espada 2, Rik Joos 2, Jonathan Akikusa 2, Jeffrey Chaitow 2, Maria Luz Gámir Gámir 2, Yukiko Kimura 3, Christoph Rietschel 2, Daniel Siri 2, Elzbieta Smolewska 2, Heinrike Schmeling 1, Diane Brown 1, Fabrizio De Benedetti 4, Daniel J. Lovell 5, Bin Huang 1 and Nicolino Ruperto 2, 1Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 3Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, 4Bambino Gesù Children’s Hospital, Rome, Italy, 5Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati

    Background/Purpose: Tocilizumab (TCZ) was approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) based on the results of…
  • Abstract Number: 2715 • 2019 ACR/ARP Annual Meeting

    Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset

    Ruth Costello1, Janet McDonagh 2, Will Dixon 1, Kimme Hyrich 2 and Jenny Humphreys 1, 1Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, 2Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common childhood onset inflammatory arthritis.  The last estimates of incidence of this disease in the United Kingdom…
  • Abstract Number: 785 • 2019 ACR/ARP Annual Meeting

    Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience

    Muhammad Shipa1, Anastasia-vasiliki Madenidou 2, vera Choida 1, Anna Radziszewska 3, corinne fisher 4, coziana ciurtin 1, maria Leandro 1 and Debajit Sen 1, 1Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, 2Centre for Adolescent Rheumatology, University College London London, UK, LOndon, 3University College London, London, United Kingdom, 4Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom

    Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
  • Abstract Number: 1925 • 2019 ACR/ARP Annual Meeting

    Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis

    Francesca Ridella 1, Giedre Januskeviciute 2, Chiara Trincianti 3, Evert Hendrik Pieter Van Dijkhuizen 4, Gabriella Giancane 5, Serena Pastore 6, Kirsten Minden 7, Maria Ekelund 8, Patrizia Barone 9, Matilda Laday 10, Nicolino Ruperto 11, Angelo Ravelli 12 and Alessandro Consolaro13, 1Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genova, Italy, 2Klaipeda Children's Hospital, Klaipeda, Lithuania, Klaipeda, Lithuania, 3Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genoa, Italy, 4Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, 5Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, 6Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, Trieste, Italy, 7German Rheumatism Research Centre Berlin, and Charité University Medicine, Department of Rheumatology and Clinical Immunology, Berlin, Germany, Berlin, Germany, 8Ryhov County Hospital, Futurum - the Academy for health and care, Jonkoping, Sweden, Jonkoping, Sweden, 9Department of Pediatrics, University of Catania, Catania, Italy, Catania, Italy, 10Spitalul Clinic Județean De Urgenta, Tîrgu-Mures, Romania, Tîrgu-Mures, Romania, 11Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 12IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 13Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy

    Background/Purpose: The assessment of disease activity plays a pivotal role in the management of children with juvenile idiopathic arthritis (JIA). Most recent recommendations require that…
  • Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting

    Long Term Outcomes of Childhood Onset Rheumatoid Arthritis

    Rebecca Overbury1, Aimee Hersh 2, CJ Inman 2, Sara Stern 2, Karen James 2 and John Bohnsack 3, 1Assisstant Professor, University of Utah, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3University of Utah School of Medicine, Salt Lake City, UT

    Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies